Completed PHASE2 INTERVENTIONAL NCT00994695

Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine (ETH-TVT)

A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians

Sponsor: Addis Ababa University

Conditions Meningococcal Meningitis

Interventions Mencevax ACW Vaccine

Updated 7 times since 2017 Last updated: Oct 15, 2009 Started: Nov 30, 2005 Primary completion: Jan 31, 2006 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Meningococcal Meningitis and is currently completed. Addis Ababa University leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Mar 2025 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Mar 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Addis Ababa University
Armauer Hansen Research Institute, Ethiopia
London School of Hygiene and Tropical Medicine
World Health Organization

Data source: Armauer Hansen Research Institute, Ethiopia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Butajīra, Ethiopia